Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharvaris N.V.

16.64
+0.08000.48%
Post-market: 16.640.00000.00%16:04 EDT
Volume:6.24K
Turnover:103.91K
Market Cap:906.77M
PE:-5.47
High:17.19
Open:16.33
Low:16.00
Close:16.56
Loading ...

Pharvaris N.v. Q1 EPS EUR -0.85 VS. Ibes Estimate EUR -0.76

THOMSON REUTERS
·
14 May

Pharvaris NV expected to post a loss of 76 cents a share - Earnings Preview

Reuters
·
03 May

Pharvaris Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

Pharvaris Nv: Kbc Securities Initiates Coverage With "Buy" Rating; Target Price $32.0

THOMSON REUTERS
·
24 Apr

Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
09 Apr

Stock Track | Pharvaris N.V. Surges 5.22% in Pre-market Following Q4 Earnings Release

Stock Track
·
08 Apr

Pharvaris Reports 2024 Financial Results and Business Progress

TIPRANKS
·
08 Apr

Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion

TIPRANKS
·
08 Apr

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

TIPRANKS
·
07 Apr

Pharvaris Reports 2024 Financial Results and Advances HAE Treatment Studies

TIPRANKS
·
07 Apr

Pharvaris Q4 2024 GAAP EPS €(0.64) Beats €(0.71) Estimate, Cash Balance Of €281M

Benzinga
·
07 Apr

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
07 Apr

Pharvaris Nv Q4 Shr View EUR -0.72 -- Lseg Ibes Data

THOMSON REUTERS
·
07 Apr

Pharvaris Nv Qtrly Loss per Share of €0.64

THOMSON REUTERS
·
07 Apr

Pharvaris NV expected to post a loss of 72 cents a share - Earnings Preview

Reuters
·
05 Apr

Pharvaris Says EU Orphan Designation Received for Deucrictibant

MT Newswires Live
·
01 Apr

Pharvaris says EC grants orphan designation to deucrictibant

TIPRANKS
·
01 Apr

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

THOMSON REUTERS
·
01 Apr

Pharvaris Price Target Maintained With a $55.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

Pharvaris reports safety and efficacy data of deucrictibant

TIPRANKS
·
03 Mar